SCHEMBL5801140

SCHEMBL5801140

Cc1c(CC(=O)O)c2cc(O)ccc2n1C(=O)c1ccc(OC(F)F)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.70
PTGS2 P35354 2/20 0.70
AKR1C3 P42330 8/20 0.65
AKR1C2 P52895 7/20 0.65
LMNA P02545 2/20 0.61
CYP1A2 P05177 2/20 0.61
CYP2D6 P10635 2/20 0.61
CYP2C9 P11712 2/20 0.61
HIF1A Q16665 2/20 0.61
NPSR1 Q6W5P4 2/20 0.61
TSHR P16473 1/20 0.61
NFKB1 P19838 1/20 0.61
AKR1C4 P17516 2/20 0.60
AKR1C1 Q04828 2/20 0.60
ABCB1 P08183 2/20 0.60
KDM4E B2RXH2 1/20 0.60
MEN1 O00255 1/20 0.60
PTGES O14684 1/20 0.60
ABCC3 O15438 1/20 0.60
ABCC4 O15439 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5554097 0.91 PTGS2 (0.61) PTGS1PTGS2AKR1C3AKR1C2LMNA
SCHEMBL5554410 0.90 AKR1C3 (0.82) PTGS1PTGS2AKR1C3AKR1C2LMNA
SCHEMBL5560008 0.90 PTGS2 (0.56) PTGS1PTGS2AKR1C3AKR1C2
SCHEMBL5560998 0.89 PTGS2 (0.62) PTGS1PTGS2AKR1C3AKR1C2
SCHEMBL5558921 0.88 PTGS2 (0.54) PTGS1PTGS2AKR1C3
SCHEMBL6426585 0.88 PTGS2 (0.55) PTGS1PTGS2AKR1C3AKR1C2
SCHEMBL5555260 0.88 PTGS2 (0.59) PTGS1PTGS2AKR1C3AKR1C2
SCHEMBL5813735 0.88 PTGS2 (0.56) PTGS1PTGS2AKR1C3AKR1C2
SCHEMBL5559442 0.87 PTGS2 (0.58) PTGS1PTGS2AKR1C3
SCHEMBL5554444 0.87 PTGS2 (0.53) PTGS1PTGS2AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481587-B2 Substituted 2-(5-hydroxy-2-methyl-1H-indole-3-yl)acetic acids and ethers thereof and the use of same to treat viral diseases IVASHCHENKO ANDREY ALEXANDROVICH (RU) 2013-07-09 US disclosed
US-8481587-B2 Substituted 2-(5-hydroxy-2-methyl-1H-indole-3-yl)acetic acids and ethers thereof and the use of same to treat viral diseases IVASHCHENKO ANDREY ALEXANDROVICH (RU) 2013-07-09 US disclosed
US-20110230524-A1 SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1H-INDOLE-3-YL)ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES ALLA CHEM, LLC. 2011-09-22 US disclosed
US-20110230524-A1 SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1H-INDOLE-3-YL)ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES ALLA CHEM, LLC. 2011-09-22 US disclosed
WO-2006050120-A2 SYNTHESIS OF COX-2 AND FAAH INHIBITORS MICROBIA, INC. (US) 2006-05-11 WO disclosed
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. 2005-10-20 US disclosed
US-20050032747-A1 COX-2 and FAAH inhibitors POLYMER CONCEPTS TECHNOLOGIES PBY, INC. 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230524-A1 SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1H-INDOLE-3-YL)ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES IDO1, TPH1, FOXM1 PTGS1 1860/4885PTGS2 3341/4885AKR1C3 53/4885
US-20050032747-A1 COX-2 and FAAH inhibitors FAAH2, FAAH, PTGS2 PTGS1 6/4885PTGS2 3/4885AKR1C3 585/4885
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors FAAH2, FAAH, PTGES2 PTGS1 7/4885PTGS2 4/4885AKR1C3 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.